UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30(1):3–16. doi:10.1055/s-0030-124712820175029
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu H, Shen XZ. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Lett. 2016;379(2):245–252. doi:10.1016/j.canlet.2015.06.02326193663
   PubMed Web of Science ®Google Scholar
• Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet. 1996;30:405–439. doi:10.1146/annurev.genet.30.1.4058982460
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem. 1992;61:761–807. doi:10.1146/annurev.bi.61.070192.0035531323239
   PubMed Web of Science ®Google Scholar
• Clague MJ, Heride C, Urbe S. The demographics of the ubiquitin system. Trends Cell Biol. 2015;25(7):417–426. doi:10.1016/j.tcb.2015.03.00225906909
   PubMed Web of Science ®Google Scholar
• Stewart MD, Ritterhoff T, Klevit RE, Brzovic PS. E2 enzymes: more than just middle men. Cell Res. 2016;26(4):423–440. doi:10.1038/cr.2016.3527002219
   PubMed Web of Science ®Google Scholar
• Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol. 2012;33(3):723–730. doi:10.1007/s13277-011-0291-122170434
   PubMedGoogle Scholar
• Voutsadakis IA. Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer. Mol Biol Rep. 2013;40(2):2019–2034. doi:10.1007/s11033-012-2261-023187732
   PubMed Web of Science ®Google Scholar
• Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589–596. doi:10.1016/j.molcel.2006.06.02416916645
   PubMed Web of Science ®Google Scholar
• Luo C, Yao Y, Yu Z, et al. UBE2T knockdown inhibits gastric cancer progression. Oncotarget. 2017;8(20):32639–32654. doi:10.18632/oncotarget.1594728427240
   PubMedGoogle Scholar
• Liu LP, Yang M, Peng QZ, et al. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 2017;493(1):20–27. doi:10.1016/j.bbrc.2017.09.09128935368
   PubMed Web of Science ®Google Scholar
• Gong YQ, Peng D, Ning XH, et al. UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 2016;12(6):4485–4492. doi:10.3892/ol.2016.523728101210
   PubMed Web of Science ®Google Scholar
• Wen M, Kwon Y, Wang Y, Mao JH, Wei G. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 2015;6(28):25226–25239. doi:10.18632/oncotarget.471226308072
   PubMedGoogle Scholar
• Ueki T, Park JH, Nishidate T, et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009;69(22):8752–8760. doi:10.1158/0008-5472.CAN-09-180919887602
   PubMed Web of Science ®Google Scholar
• Hao J, Xu A, Xie X, et al. Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 2008;29(3):195–203. doi:10.1159/00014818718667844
   PubMedGoogle Scholar
• Wege H, Le HT, Chui MS, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology. 2003;124(2):432–444. doi:10.1053/gast.2003.5006412557149
   PubMed Web of Science ®Google Scholar
• Zhou P, Lessa N, Estrada DC, et al. Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice. Liver Transpl. 2011;17(4):418–427. doi:10.1002/lt.2227021445925
   PubMed Web of Science ®Google Scholar
• Alpi A, Langevin F, Mosedale G, et al. UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol. 2007;27(24):8421–8430. doi:10.1128/MCB.00504-0717938197
   PubMed Web of Science ®Google Scholar
• Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24(30):4741–4753. doi:10.1038/sj.onc.120864115897902
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013;6(269):pl1. doi:10.1126/scisignal.200408823550210
   PubMed Web of Science ®Google Scholar
• Hu W, Xiao L, Cao C, Hua S, Wu D. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3beta/beta-catenin pathway. Oncotarget. 2016;7(12):15161–15172. doi:10.18632/oncotarget.780526943030
   PubMedGoogle Scholar
• Yu H, Xiang P, Pan Q, et al. Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol. 2016;37(9):11723–11732. doi:10.1007/s13277-016-5020-327020591
   PubMedGoogle Scholar
• Wang Y, Leng H, Chen H, et al. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol Res. 2016;24(5):361–369. doi:10.3727/096504016X1468503410331027712593
   PubMed Web of Science ®Google Scholar
• Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25(1):114–132. doi:10.1038/cdd.2017.17229125603
   PubMed Web of Science ®Google Scholar
• Sisinni L, Maddalena F, Condelli V, et al. TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. J Pathol. 2017;243(1):123–134. doi:10.1002/path.493628678347
   PubMed Web of Science ®Google Scholar
• Jackson RJ, Adnane J, Coppola D, et al. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 2002;21(55):8486–8497. doi:10.1038/sj.onc.120594612466968
   PubMed Web of Science ®Google Scholar
• Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol. 2015;21(42):12150–12156. doi:10.3748/wjg.v21.i42.1215026576099
   PubMed Web of Science ®Google Scholar
• Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52–58. doi:10.1097/CCO.0b013e32835b639e23159848
   PubMed Web of Science ®Google Scholar
• Serres MP, Zlotek-Zlotkiewicz E, Concha C, et al. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene. 2011;30(25):2846–2858. doi:10.1038/onc.2011.921317921
   PubMed Web of Science ®Google Scholar